Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
XTX301 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT05684965
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸HealthPartners Frauenshuh Cancer center, Saint Louis Park, Minnesota, United States
XTX202 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05052268
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: vilastobart (XTX101)
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT04896697
- Locations
- 🇺🇸
Mayo Clinic Hospital, Rochester, Minnesota, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸California Cancer Associates for Research and Excellence, cCARE, San Marcos, California, United States